These data indicate that PPP2R2B may serve as a reliable biomarker to predict the clinical outcomes of patients with BC treated using cisplatin and that SUV39H1 inhibitor is a potential strategy to overcome cisplatin resistance. The gene discussed is PPP2R2B; the disease is breast cancer.